过氧化物酶体增殖物激活受体γ共激活因子1α作为双相障碍及其他神经精神障碍的新靶点
本文综述PGC-1α与PPARs的生理功能及其在神经退行性疾病和双相障碍中的作用,并回顾已上市降糖药噻唑烷二酮类和降甘油三酯贝特类(PPAR激动剂)用于这些疾病的临床试验,提出PGC-1α与PPARs是双相障碍的创新潜在靶点,值得未来开展临床试验。
要点
- PGC-1α通过激活PPARs调控代谢、炎症、线粒体生物合成与脑能量代谢。
- 双相障碍及多种神经退行性疾病与线粒体和脑能量代谢失调相关。
- PPAR激动剂(噻唑烷二酮类、贝特类)再定位治疗双相障碍值得未来临床试验。
核心结论
- PGC-1α与PPARs是双相障碍的创新潜在治疗靶点,值得未来开展临床试验。
研究设计与样本
- 本文为综述,回顾PGC-1α与PPARs的生理学及其作为治疗靶点的作用。
- 综述还回顾了噻唑烷二酮类和贝特类(PPAR激动剂)用于神经退行性疾病和双相障碍的临床试验。
主要发现
- PGC-1α通过激活核受体(尤其是PPAR家族)调控代谢与炎症。
- PGC-1α与PPARs还调控线粒体生物合成、细胞能量产生、产热和脂质代谢。
- 脑能量代谢可能部分由PGC-1α与PPARs的相互作用调控。
- 神经退行性疾病(亨廷顿病、帕金森病、肌萎缩侧索硬化)和双相障碍与线粒体和脑能量代谢失调相关。
临床怎么用
- 提示临床可关注PPAR激动剂(如噻唑烷二酮类、贝特类)在双相障碍中的再定位研究证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1 alpha) is a protein that regulates metabolism and inflammation by activating nuclear receptors, especially the family of peroxisome proliferator-activated receptors (PPARs). PGC-1 alpha and PPARs also regulate mitochondrial biogenesis, cellular energy production, thermogenesis, and lipid metabolism. Brain energy metabolism may also be regulated in part by the interaction between PGC-1 alpha and PPARs. Because neurodegenerative diseases (Huntington's disease, Parkinson's disease, and amyotrophic lateral sclerosis) and bipolar disorder have been associated with dysregulated mitochondrial and brain energy metabolism, PGC-1 alpha may represent a potential drug target for these conditions. The purpose of this article is to review the physiology of PGC-1 alpha, PPARs, and the role of PPAR agonists to target PGC-1 alpha to treat neurodegenerative diseases and bipolar disorder. We also review clinical trials of repurposed antidiabetic thiazolidines and anti-triglyceride fibrates (PPAR agonists) for neurodegenerative diseases and bipolar disorder. PGC-1 alpha and PPARs are innovative potential targets for bipolar disorder and warrant future clinical trials.
引用
- Nierenberg AA, Ghaznavi SA, Sande Mathias I, et al. Peroxisome Proliferator-Activated Receptor Gamma Coactivator-1 Alpha as a Novel Target for Bipolar Disorder and Other Neuropsychiatric Disorders. Biol Psychiatry. 2018. PMID: 29502862. doi:10.1016/j.biopsych.2017.12.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。